Purpose
This study develops and evaluates a systematic approach to finding biomarker genes for predicting potency of anticancer drugs against tumor cells, focusing on gene families related to growth factor signaling.
Methods
Cytotoxic potencies of 119 drugs against 60 neoplastic cell lines (NCI-60) were correlated with expression of 343 genes, including 90 growth factors and receptors, 63 metalloproteinases, and 92 ras-like GTPases as downstream signaling factors. Progressively more stringent criteria and predictive models aim at identifying the smallest subset of genes predictive of cytotoxic potency.
Results
Comparing gene expression with drug potency across the NCI-60 yielded genes with negative and positive correlations (p < 0.001), indicative of a role in chemoresistance and chemosensitivity, respectively. Of 17 genes with multiple negative correlations, 8 are known chemoresistance factors, validating the approach. Negatively correlated genes clustered into two main groups with distinct expression profiles and drug correlations, represented by EGFR and ERBB2 (Her-2/Neu). Accordingly, no synergism was observed between EGFR and ERBB2 inhibitors. However, combinations with classical anticacer drugs were not correlated with EGFR and ERBB2 expression in four cell lines tested, suggesting complex interactions in combination treatments. Finally, a subset of only 13 genes was found to be sufficient for near optimal prediction of drug potency against the NCI-60.
Conclusions
Our approach using a small subset of genes reveals known and potential biomarkers in cancer chemotherapy, providing a strategy for genome-wide analysis.
Similar content being viewed by others
References
A. Wallqvist A. A. Rabow R. H. Shoemaker E. A. Sausville D. G. Covell (2002) ArticleTitleEstablishing connections between microarray expression data and chemotherapeutic cancer pharmacology Mol. Cancer Ther. 1 311–320 Occurrence Handle1:CAS:528:DC%2BD38XjtFWmsrk%3D Occurrence Handle12489847
R. L. Strausberg A. J. Simpson L. J. Old G. J. Riggins (2004) ArticleTitleOncogenomics and the development of new cancer therapies Nature 429 469–474 Occurrence Handle10.1038/nature02627 Occurrence Handle1:CAS:528:DC%2BD2cXkt1Onsbs%3D Occurrence Handle15164073
N. J. Winick W. L. Carroll S. P. Hunger (2004) ArticleTitleChildhood leukemia—new advances and challenges N. Engl. J. Med. 351 601–603 Occurrence Handle10.1056/NEJMe048154 Occurrence Handle1:CAS:528:DC%2BD2cXmtF2qsr8%3D Occurrence Handle15295054
C. H. Lee P. F. Macgregor (2004) ArticleTitleUsing microarrays to predict resistance to chemotherapy in cancer patients Pharmacogenomics 5 611–625 Occurrence Handle10.1517/14622416.5.6.611 Occurrence Handle1:CAS:528:DC%2BD2cXmvFOmtLw%3D Occurrence Handle15335284
C. Sawyers (2004) ArticleTitleTargeted cancer therapy Nature 432 294–297 Occurrence Handle10.1038/nature03095 Occurrence Handle1:CAS:528:DC%2BD2cXpvVCjtL8%3D Occurrence Handle15549090
D. W. Nebert E. S. Vesell (2004) ArticleTitleAdvances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead Eur. J. Pharmacol. 500 267–280 Occurrence Handle10.1016/j.ejphar.2004.07.031 Occurrence Handle1:CAS:528:DC%2BD2cXotFClu7Y%3D Occurrence Handle15464039
J. K. Lee K. J. Bussey F. G. Gwadry W. Reinhold G. Riddick S. L. Pelletier S. Nishizuka G. Szakacs J. P. Annereau U. Shankavaram S. Lababidi L. H. Smith M. M. Gottesman J. N. Weinstein (2003) ArticleTitleComparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells Genome Biol. 4 R82 Occurrence Handle14659019
A. Holleman M. H. Cheok M. L. Boerden W. Yang A. J. Veerman K. M. Kazemier D. Pei C. Cheng C. H. Pui M. V. Relling G. E. Janka-Schaub R. Pieters W. E. Evans (2004) ArticleTitleGene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment N. Engl. J. Med. 351 533–542 Occurrence Handle10.1056/NEJMoa033513 Occurrence Handle1:CAS:528:DC%2BD2cXmtF2rtb8%3D Occurrence Handle15295046
C. D. Britten (2004) ArticleTitleTargeting ErbB receptor signaling: a pan-ErbB approach to cancer Mol. Cancer Ther. 3 1335–1342 Occurrence Handle1:CAS:528:DC%2BD2cXosVSrsLo%3D Occurrence Handle15486201
B. Jansen H. Schlagbauer-Wadl H. G. Eichler K. Wolff A. Elsas Particlevan P. I. Schrier H. Pehamberger (1997) ArticleTitleActivated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis Cancer Res. 57 362–365 Occurrence Handle1:CAS:528:DyaK2sXhtVGlt7c%3D Occurrence Handle9012455
R. Sanchez-Prieto J. A. Vargas A. Carnero E. Marchetti J. Romero A. Durantez J. C. Lacal S. Ramon y Cajal (1995) ArticleTitleModulation of cellular chemoresistance in keratinocytes by activation of different oncogenes Int. J. Cancer 60 235–243 Occurrence Handle1:CAS:528:DyaK2MXksF2qu7g%3D Occurrence Handle7829222
R. S. Herbst M. Fukuoka J. Baselga (2004) ArticleTitleTimeline: gefitinib—a novel targeted approach to treating cancer Nat. Rev., Cancer 4 956–965 Occurrence Handle10.1038/nrc1506 Occurrence Handle1:CAS:528:DC%2BD2cXhtVarsLjJ
R. Nahta F. J. Esteva (2003) ArticleTitleHER-2-targeted therapy: lessons learned and future directions Clin. Cancer Res. 9 5078–5084 Occurrence Handle1:CAS:528:DC%2BD3sXovVOgtb4%3D Occurrence Handle14613984
N. Dandachi O. Dietze C. Hauser-Kronberger (2004) ArticleTitleEvaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer Anticancer Res. 24 2401–2406 Occurrence Handle15330190
Z. Dai Y. Huang W. Sadee (2004) ArticleTitleGrowth factor signaling and resistance to cancer chemotherapy Curr. Top. Med. Chem. 4 1347–1356 Occurrence Handle10.2174/1568026043387746 Occurrence Handle1:CAS:528:DC%2BD2cXnslCms78%3D Occurrence Handle15379649
P. Hersey X. D. Zhang (2003) ArticleTitleOvercoming resistance of cancer cells to apoptosis J. Cell. Physiol. 196 9–18 Occurrence Handle10.1002/jcp.10256 Occurrence Handle1:CAS:528:DC%2BD3sXksFehtrw%3D Occurrence Handle12767037
J. M. Yang A. D. Vassil W. N. Hait (2001) ArticleTitleActivation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf–MAPK pathway Mol. Pharmacol. 60 674–680 Occurrence Handle1:CAS:528:DC%2BD3MXnt1ekurc%3D Occurrence Handle11562428
M. C. Prewett A. T. Hooper R. Bassi L. M. Ellis H. W. Waksal D. J. Hicklin (2002) ArticleTitleEnhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts Clin. Cancer Res. 8 994–1003 Occurrence Handle1:CAS:528:DC%2BD38XksVSqur8%3D Occurrence Handle12006511
F. Ciardiello R. Caputo R. Bianco V. Damiano G. Pomatico S. Placido ParticleDe A. R. Bianco G. Tortora (2000) ArticleTitleAntitumor effect and potentiation of cytotoxic drugs activity in human cancer cells byZD-1839 (Iressa), an epidermal growth factor receptor-selectivetyrosine kinase inhibitor Clin. Cancer Res. 6 2053–2063 Occurrence Handle1:CAS:528:DC%2BD3cXktVWitrs%3D Occurrence Handle10815932
F. M. Sirotnak M. F. Zakowski V. A. Miller H. I. Scher M. G. Kris (2000) ArticleTitleEfficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin. Cancer Res. 6 4885–4892 Occurrence Handle1:CAS:528:DC%2BD3MXotlektQ%3D%3D Occurrence Handle11156248
Y. Lu X. Zi Y. Zhao D. Mascarenhas M. Pollak (2001) ArticleTitleInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J. Natl. Cancer Inst. 93 1852–1857 Occurrence Handle10.1093/jnci/93.24.1852 Occurrence Handle1:CAS:528:DC%2BD38XltVWluw%3D%3D Occurrence Handle11752009
C. Knuefermann Y. Lu B. Liu W. Jin K. Liang L. Wu M. Schmidt G. B. Mills J. Mendelsohn Z. Fan (2003) ArticleTitleHER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells Oncogene 22 3205–3212 Occurrence Handle10.1038/sj.onc.1206394 Occurrence Handle1:CAS:528:DC%2BD3sXjvFaksLo%3D Occurrence Handle12761490
I. Vivanco C. L. Sawyers (2002) ArticleTitleThe phosphatidylinositol 3-kinase AKT pathway in human cancer Nat. Rev., Cancer 2 489–501 Occurrence Handle10.1038/nrc839 Occurrence Handle1:CAS:528:DC%2BD38XkvFKltLs%3D
A. Monks D. Scudiero P. Skehan R. Shoemaker K. Paull D. Vistica C. Hose J. Langley P. Cronise A. Vaigro-Wolff et al. (1991) ArticleTitleFeasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Natl. Cancer Inst. 83 757–766 Occurrence Handle1:CAS:528:DyaK3MXksVWiuro%3D Occurrence Handle2041050
U. Scherf D. T. Ross M. Waltham L. H. Smith J. K. Lee L. Tanabe K. W. Kohn W. C. Reinhold T. G. Myers D. T. Andrews D. A. Scudiero M. B. Eisen E. A. Sausville Y. Pommier D. Botstein P. O. Brown J. N. Weinstein (2000) ArticleTitleA gene expression database for the molecular pharmacology of cancer Nat. Genet. 24 236–244 Occurrence Handle1:CAS:528:DC%2BD3cXhvFaqtrk%3D Occurrence Handle10700175
A. J. Butte P. Tamayo D. Slonim T. R. Golub I. S. Kohane (2000) ArticleTitleDiscovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevancenetworks Proc. Natl. Acad. Sci. USA 97 12182–12186 Occurrence Handle10.1073/pnas.220392197 Occurrence Handle1:CAS:528:DC%2BD3cXnvVSgtbY%3D Occurrence Handle11027309
A. A. Rabow R. H. Shoemaker E. A. Sausville D. G. Covell (2002) ArticleTitleMining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities J. Med. Chem. 45 818–840 Occurrence Handle10.1021/jm010385b Occurrence Handle1:CAS:528:DC%2BD38XlvFSitg%3D%3D Occurrence Handle11831894
J. E. Staunton D. K. Slonim H. A. Coller P. Tamayo M. J. Angelo J. Park U. Scherf J. K. Lee W. O. Reinhold J. N. Weinstein J. P. Mesirov E. S. Lander T. R. Golub (2001) ArticleTitleChemosensitivity prediction by transcriptional profiling Proc. Natl. Acad. Sci. USA 98 10787–10792 Occurrence Handle10.1073/pnas.191368598 Occurrence Handle1:CAS:528:DC%2BD3MXntVGmsL4%3D Occurrence Handle11553813
Y. Huang P. Anderle K. J. Bussey C. Barbacioru U. Shankavaram Z. Dai W. C. Reinhold A. Papp J. N. Weinstein W. Sadee (2004) ArticleTitleMembrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance Cancer Res. 64 4294–4301 Occurrence Handle1:CAS:528:DC%2BD2cXkvFWlsbo%3D Occurrence Handle15205344
Y. Huang P. E. Blower C. Yang C. Barbacioru Z. Dai Y. Zhang J. J. Xiao K. K. Chan W. Sadée (2005) ArticleTitleCorrelating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1 (ABCB1) Pharmacogenomics J. 5 112–125 Occurrence Handle1:CAS:528:DC%2BD2MXitlCmsbk%3D Occurrence Handle15668728
P. Anderle V. Rakhmanova K. Woodford N. Zerangue W. Sadee (2003) ArticleTitleMessenger RNA expression of transporter and ionchannel genes in undifferentiated and differentiated Caco-2cellscompared to human intestines Pharm. Res. 20 3–15 Occurrence Handle10.1023/A:1022282221530 Occurrence Handle1:CAS:528:DC%2BD3sXoslKitA%3D%3D Occurrence Handle12608530
J. N. Weinstein K. W. Kohn M. R. Grever V. N. Viswanadhan L. V. Rubinstein A. P. Monks D. A. Scudiero L. Welch A. D. Koutsoukos A. J. Chiausa (1992) ArticleTitleNeural computing in cancer drug development: predicting mechanism of action Science 258 447–451 Occurrence Handle1:CAS:528:DyaK38Xmt1Glt7w%3D Occurrence Handle1411538
B. Efron R. J. Tibshirani (1993) An Introduction to the Bootstrap Chapman & Hall, Inc. New York
Y. Benjamini Y. Hochberg (1995) ArticleTitleControlling the false discovery rate: a practical and powerful approach to multiple testing J. R. Stat. Soc., B 57 289–300
J. N. Weinstein T. G. Myers P. M. O'Connor S. H. Friend A. J. Fornace SuffixJr. K. W. Kohn T. Fojo S. E. Bates L. V. Rubinstein N. L. Anderson J. K. Buolamwini W. W. Osdol Particlevan A. P. Monks D. A. Scudiero E. A. Sausville D. W. Zaharevitz B. Bunow V. N. Viswanadhan G. S. Johnson R. E. Wittes K. D. Paull (1997) ArticleTitleAn information-intensive approach to the molecular pharmacology of cancer Science 275 343–349 Occurrence Handle10.1126/science.275.5298.343 Occurrence Handle1:CAS:528:DyaK2sXmtlCitg%3D%3D Occurrence Handle8994024
M. B. Eisen P. T. Spellman P. O. Brown D. Botstein (1998) ArticleTitleCluster analysis and display of genome-wide expression patterns Proc. Natl. Acad. Sci. USA 95 14863–14868 Occurrence Handle10.1073/pnas.95.25.14863 Occurrence Handle1:CAS:528:DyaK1cXotVGmurk%3D Occurrence Handle9843981
P. Skehan R. Storeng D. Scudiero A. Monks J. McMahon D. Vistica J. T. Warren H. Bokesch S. Kenney M. R. Boyd (1990) ArticleTitleNew colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1107–1112 Occurrence Handle1:CAS:528:DyaK3cXltVylsL8%3D Occurrence Handle2359136
T. C. Chou P. Talalay (1984) ArticleTitleQuantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 27–55 Occurrence Handle1:CAS:528:DyaL2cXktlaksLk%3D Occurrence Handle6382953
J. Topaly S. Fruehauf A. D. Ho W. J. Zeller (2002) ArticleTitleRationale forcombination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning Br. J. Cancer 86 1487–1493 Occurrence Handle10.1038/sj.bjc.6600242 Occurrence Handle1:CAS:528:DC%2BD38XkvVKjsbs%3D Occurrence Handle11986785
C. P. Landowski P. Anderle D. Sun W. Sadee G. L. Amidon (2004) ArticleTitleTransporter and ion channel gene expression after Caco-2 cell differentiation using 2 different microarray technologies AAPS J. 6 e21 Occurrence Handle10.1208/aapsj060321 Occurrence Handle15760106
S. Dan T. Tsunoda O. Kitahara R. Yanagawa H. Zembutsu T. Katagiri K. Yamazaki Y. Nakamura T. Yamori (2002) ArticleTitleAn integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines Cancer Res. 62 1139–1147 Occurrence Handle1:CAS:528:DC%2BD38XitVSmtrg%3D Occurrence Handle11861395
T. J. Lynch D. W. Bell R. Sordella S. Gurubhagavatula R. A. Okimoto B. W. Brannigan P. L. Harris S. M. Haserlat J. G. Supko F. G. Haluska D. N. Louis D. C. Christiani J. Settleman D. A. Haber (2004) ArticleTitleActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2129–2139 Occurrence Handle10.1056/NEJMoa040938 Occurrence Handle1:CAS:528:DC%2BD2cXktF2js7c%3D Occurrence Handle15118073
M. Schmidt R. B. Lichtner (2002) ArticleTitleEGF receptor targeting in therapy-resistant human tumors Drug Resist. Updat. 5 11–18 Occurrence Handle1:CAS:528:DC%2BD38XoslSqtLc%3D Occurrence Handle12127860
D. Yu M. C. Hung (2000) ArticleTitleRole of erbB2 in breast cancer chemosensitivity BioEssays 22 673–680 Occurrence Handle10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A Occurrence Handle1:CAS:528:DC%2BD3MXmslWlt7w%3D Occurrence Handle10878580
D. Yu (2001) ArticleTitleMechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers Semin. Oncol. 28 IssueID(5 Suppl 16) 12–17 Occurrence Handle1:CAS:528:DC%2BD3MXpt1Wgu78%3D Occurrence Handle11706391
M. Sumitomo T. Asano J. Asakuma A. Horiguchi M. Hayakawa (2004) ArticleTitleZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway Clin. Cancer Res. 10 794–801 Occurrence Handle1:CAS:528:DC%2BD2cXovVKitA%3D%3D Occurrence Handle14760103
M. D. Pegram D. J. Slamon (1999) ArticleTitleCombination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity Semin. Oncol. 26 IssueID(4 Suppl 12) 89–95 Occurrence Handle1:CAS:528:DyaK1MXmt1Sitr8%3D Occurrence Handle10482199
M. S. Tsai A. E. Hornby J. Lakins R. Lupu (2000) ArticleTitleExpression and function of CYR61, an angiogenic factor, in breast cancercell lines and tumor biopsies Cancer Res. 60 5603–5607 Occurrence Handle1:CAS:528:DC%2BD3cXnvVSnsL8%3D Occurrence Handle11059746
J. A. Menendez I. Mehmi D. W. Griggs R. Lupu (2003) ArticleTitleThe angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives Endocr. Relat. Cancer 10 141–152 Occurrence Handle10.1677/erc.0.0100141 Occurrence Handle1:CAS:528:DC%2BD3sXmsFCku7c%3D Occurrence Handle12790776
M. T. Lin C. C. Chang S. T. Chen H. L. Chang J. L. Su Y. P. Chau M. L. Kuo (2004) ArticleTitleCyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation J. Biol. Chem. 279 24015–24023 Occurrence Handle1:CAS:528:DC%2BD2cXksV2is74%3D Occurrence Handle15044484
H. Osada T. Tokunaga M. Nishi H. Hatanaka Y. Abe A. Tsugu H. Kijima H. Yamazaki Y. Ueyama M. Nakamura (2004) ArticleTitleOverexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma Anticancer Res. 24 547–552 Occurrence Handle1:CAS:528:DC%2BD2cXkvVegtbs%3D Occurrence Handle15160992
M. Klagsbrun S. Takashima R. Mamluk (2002) ArticleTitleThe role of neuropilin in vascular and tumor biology Adv. Exp. Med. Biol. 515 33–48 Occurrence Handle1:CAS:528:DC%2BD3sXisl2jsLw%3D Occurrence Handle12613541
C. B. Brown A. S. Boyer R. B. Runyan J. V. Barnett (1999) ArticleTitleRequirement of type III TGF-beta receptor for endocardial cell transformation in the heart Science 283 2080–2082 Occurrence Handle1:CAS:528:DyaK1MXit12gtLg%3D Occurrence Handle10092230
F. Lopez-Casillas J. L. Wrana J. Massague (1993) ArticleTitleBetaglycan presents ligand to the TGF beta signaling receptor Cell 73 1435–1444 Occurrence Handle1:CAS:528:DyaK3sXkvVOhsLw%3D Occurrence Handle8391934
A. Tannapfel K. Anhalt P. Hausermann F. Sommerer M. Benicke D. Uhlmann H. Witzigmann J. Hauss C. Wittekind (2003) ArticleTitleIdentification of novel proteins associated with hepatocellular carcinomas using protein microarrays J. Pathol. 201 238–249 Occurrence Handle10.1002/path.1420 Occurrence Handle1:CAS:528:DC%2BD3sXovVCrtrc%3D Occurrence Handle14517841
R. Grutzmann J. Luttges B. Sipos O. Ammerpohl F. Dobrowolski I. Alldinger S. Kersting D. Ockert R. Koch H. Kalthoff H. K. Schackert H. D. Saeger G. Kloppel C. Pilarsky (2004) ArticleTitleADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma Br. J. Cancer 90 1053–1058 Occurrence Handle1:STN:280:DC%2BD2c7gsFaksw%3D%3D Occurrence Handle14997207
O. M. Fischer S. Hart A. Gschwind N. Prenzel A. Ullrich (2004) ArticleTitleOxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor Mol. Cell. Biol. 24 5172–5183 Occurrence Handle10.1128/MCB.24.12.5172-5183.2004 Occurrence Handle1:CAS:528:DC%2BD2cXkvFOqtrs%3D Occurrence Handle15169883
Y. Izumi M. Hirata H. Hasuwa R. Iwamoto T. Umata K. Miyado Y. Tamai T. Kurisaki A. Sehara-Fujisawa S. Ohno E. Mekada (1998) ArticleTitleA metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor EMBO J. 17 7260–7272 Occurrence Handle10.1093/emboj/17.24.7260 Occurrence Handle1:STN:280:DyaK1M%2FnslOqtg%3D%3D Occurrence Handle9857183
J. Zuber O. I. Tchernitsa B. Hinzmann A. C. Schmitz M. Grips M. Hellriegel C. Sers A. Rosenthal R. Schafer (2000) ArticleTitleA genome-wide survey of RAS transformation targets Nat. Genet. 24 144–152 Occurrence Handle1:CAS:528:DC%2BD3cXhtFCgsbs%3D Occurrence Handle10655059
A. Chakravarti A. Chakladar M. A. Delaney D. E. Latham J. S. Loeffler (2002) ArticleTitleThe epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res. 62 4307–4315 Occurrence Handle1:CAS:528:DC%2BD38XlvFeltbY%3D Occurrence Handle12154034
G. A. Murphy S. M. Graham S. Morita S. E. Reks K. Rogers-Graham A. Vojtek G. G. Kelley C. J. Der (2002) ArticleTitleInvolvement ofphosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation J. Biol. Chem. 277 9966–9975 Occurrence Handle1:CAS:528:DC%2BD38XisVylsbc%3D Occurrence Handle11788587
R. Rong Q. He Y. Liu M. S. Sheikh Y. Huang (2002) ArticleTitleTC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-kappaB signaling pathway Oncogene 21 1062–1070 Occurrence Handle10.1038/sj.onc.1205154 Occurrence Handle1:CAS:528:DC%2BD38XhvFGqs7Y%3D Occurrence Handle11850823
D. H. Kozian H. G. Augustin (1997) ArticleTitleTranscriptional regulation of the Ras-related protein TC21/R-Ras2 in endothelial cells FEBS Lett. 414 239–242 Occurrence Handle10.1016/S0014-5793(97)01038-7 Occurrence Handle1:CAS:528:DyaK2sXlslChsbk%3D Occurrence Handle9315693
S. Song M. G. Wientjes Y. Gan J. L. Au (2000) ArticleTitleFibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs Proc. Natl. Acad. Sci. USA 97 8658–8663 Occurrence Handle1:CAS:528:DC%2BD3cXlt1GnsLg%3D Occurrence Handle10890892
Y. Chien M. A. White (2003) ArticleTitleRAL GTPases are linchpin modulators of human tumour-cell proliferation and survival EMBO Rep. 4 800–806 Occurrence Handle10.1038/sj.embor.embor899 Occurrence Handle1:CAS:528:DC%2BD3sXmvFyksLg%3D Occurrence Handle12856001
E. A. Clark T. R. Golub E. S. Lander R. O. Hynes (2000) ArticleTitleGenomic analysis of metastasis reveals an essential role for RhoC Nature 406 532–535 Occurrence Handle1:CAS:528:DC%2BD3cXmtFensbo%3D Occurrence Handle10952316
K. L. Golen Particlevan L. W. Bao Q. Pan F. R. Miller Z. F. Wu S. D. Merajver (2002) ArticleTitleMitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer Clin. Exp. Metastasis 19 301–311 Occurrence Handle12090470
N. Normanno M. Campiglio L. A. De G. Somenzi M. Maiello F. Ciardiello L. Gianni D. S. Salomon S. Menard (2002) ArticleTitleCooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Ann. Oncol. 13 65–72 Occurrence Handle10.1093/annonc/mdf020 Occurrence Handle1:STN:280:DC%2BD387islyksg%3D%3D Occurrence Handle11863114
A. J. Danielsen N. J. Maihle (2002) ArticleTitleThe EGF/ErbB receptor family and apoptosis Growth Factors 20 1–15 Occurrence Handle10.1080/08977190290022185 Occurrence Handle1:CAS:528:DC%2BD38XjvV2gt7k%3D Occurrence Handle11999214
J. P. Steinbach A. Klumpp H. Wolburg M. Weller (2004) ArticleTitleInhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death Cancer Res. 64 1575–1578 Occurrence Handle10.1158/0008-5472.CAN-03-3775 Occurrence Handle1:CAS:528:DC%2BD2cXhslektLk%3D Occurrence Handle14996711
V. Smith S. Hobbs W. Court S. Eccles P. Workman L. R. Kelland (2002) ArticleTitleErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin Anticancer Res. 22 1993–1999 Occurrence Handle1:CAS:528:DC%2BD38XmsF2lsb8%3D Occurrence Handle12174876
A. E. Wakeling S. P. Guy J. R. Woodburn S. E. Ashton B. J. Curry A. J. Barker K. H. Gibson (2002) ArticleTitleZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with otential for cancer therapy Cancer Res. 62 5749–5754 Occurrence Handle1:CAS:528:DC%2BD38XotFyktr8%3D Occurrence Handle12384534
J. G. Paez P. A. Janne J. C. Lee S. Tracy H. Greulich S. Gabriel P. Herman F. J. Kaye N. Lindeman T. J. Boggon K. Naoki H. Sasaki Y. Fujii M. J. Eck W. R. Sellers B. E. Johnson M. Meyerson (2004) ArticleTitleEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497–1500 Occurrence Handle10.1126/science.1099314 Occurrence Handle1:CAS:528:DC%2BD2cXksVGmsbs%3D Occurrence Handle15118125
R. Fukazawa T. A. Miller Y. Kuramochi S. Frantz Y. D. Kim M. A. Marchionni R. A. Kelly D. B. Sawyer (2003) ArticleTitleNeuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt J. Mol. Cell. Cardiol. 35 1473–1479 Occurrence Handle10.1016/j.yjmcc.2003.09.012 Occurrence Handle1:CAS:528:DC%2BD3sXpsVSntr0%3D Occurrence Handle14654373
Q. W. Fan K. M. Specht C. Zhang D. D. Goldenberg K. M. Shokat W. A. Weiss (2003) ArticleTitleCombinatorial efficacy achieved through two-point blockade within a signaling pathway—a chemical genetic approach Cancer Res. 63 8930–8938 Occurrence Handle1:CAS:528:DC%2BD3sXhtVSqtbjI Occurrence Handle14695210
P. M. Navolanic L. S. Steelman J. A. McCubrey (2003) ArticleTitleEGFR family signaling and its association with breast cancer development and resistance to chemotherapy (review) Int. J. Oncol. 22 237–252 Occurrence Handle1:CAS:528:DC%2BD3sXhtV2ltr0%3D Occurrence Handle12527919
S. W. Kim M. Hayashi J. F. Lo Y. Yang J. S. Yoo J. D. Lee (2003) ArticleTitleADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation J. Biol. Chem. 278 2661–2668 Occurrence Handle1:CAS:528:DC%2BD3sXksFaksg%3D%3D Occurrence Handle12446727
Acknowledgments
This study was in part supported by NIH grant GM61390 (WS, member, Plasma Membrane Transport Group at UCSF), funds from The Ohio State University, the Cardiovascular Bioengineering Enterprise at The Ohio State University of Ohio Tobacco Settlement (BRTT), and the Ohio Biomed Research & Technology grant “Biomedical Informatics Synthesis Platform.”
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Dai, Z., Barbacioru, C., Huang, Y. et al. Prediction of Anticancer Drug Potency from Expression of Genes Involved in Growth Factor Signaling. Pharm Res 23, 336–349 (2006). https://doi.org/10.1007/s11095-005-9260-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-005-9260-y